Research Topics
| Donald S KaufmanSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapyDonald S Kaufman
Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, USA
N Engl J Med 351:171-8. 2004
Bladder cancerDonald S Kaufman
Department of Medicine, the Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
Lancet 374:239-49. 2009..We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted therapies, and advances in molecular biology...- Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman
Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Urology 73:833-7. 2009..To evaluate the safety, tolerance, protocol completion rate, tumor response rate, and patient survival of chemoradiotherapy for patients with muscle-invasive operable bladder cancer... 
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06Jason A Efstathiou
Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 3, Boston, MA 02114, USA
J Clin Oncol 27:4055-61. 2009..We investigated late pelvic toxicity after chemoradiotherapy for patients treated on prospective protocols...- Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experienceJason A Efstathiou
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Eur Urol 61:705-11. 2012..Whether organ-conserving treatment by combined-modality therapy (CMT) achieves comparable long-term survival to radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) is largely unknown... - The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?Jennifer Y Wo
Harvard Radiation Oncology Programm, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
BJU Int 104:179-83. 2009.... - Bladder preservation: optimizing radiotherapy and integrated treatment strategiesRaymond H Mak
Department of Radiation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
BJU Int 102:1345-53. 2008..Future work will continue to refine the bladder-preserving approach to improve survival and local control... - Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-upWilliam K Oh
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Urology 62:99-104. 2003..Furthermore, castration induces secondary responses that may be of shorter duration than if started initially, although the overall period of hormonally responsive prostate cancer is more than 4 years... - Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancerHenry K Tsai
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Urology 68:1188-92. 2006..To assess whether statin use improves local control (LC) in patients undergoing organ-preserving trimodality therapy for muscle-invasive bladder cancer... - Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancerDonald S Kaufman
Department of Hematology-Oncology, Massachusetts General Hospital, USA
N Engl J Med 356:2515-20. 2007 - Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapyMatthew R Smith
Massachusetts General Hospital, Cancer Center, Boston MA 02114, USA
J Clin Oncol 24:2723-8. 2006..To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable... - Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancerM Dror Michaelson
Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer 107:530-5. 2006..Atrasentan is an investigational agent that inhibits endothelin-1 receptor, resulting in decreased osteoblast activity... - Bladder-sparing approaches to invasive diseaseJason A Efstathiou
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
World J Urol 24:517-29. 2006..Future work will continue to optimize the bladder-sparing regimen while limiting toxicity... - Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerM Dror Michaelson
Division of Hematology and Oncology and Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 25:1038-42. 2007..Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known... - Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapyRobert W Ross
Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Imaging 33:301-5. 2009..Six (23%) of the 26 patients, previously believed to be node negative, tested lymph node positive by LNMRI. A total of nine positive lymph nodes were identified in these six patients, none of which were enlarged based on size criteria... - Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancerJairam R Eswara
Department of Urology, Massachusetts General Hospital, Boston, MA, USA
J Urol 187:463-8. 2012..Salvage cystectomy is reserved for those in whom combined modality therapy fails. We characterized complications associated with salvage cystectomy... - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladderDonald S Kaufman
Division of Hematology-Oncology, Massachusetts General Hospital, USA
N Engl J Med 350:394-402. 2004 - Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapyMatthew R Smith
Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston 02114, USA
Cancer 101:1569-74. 2004.... - Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiencesWilliam U Shipley
Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02138, USA
Semin Radiat Oncol 15:36-41. 2005..This preserves the urinary diversion options open to the surgeon as well as brings forward the time to a salvage procedure should it be needed... - Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancerMichael J Barry
Department of Medicine, Massachusetts General Hospital, USA
N Engl J Med 358:2161-8. 2008 - Case records of the Massachusetts General Hospital. Case 6-2007. A 28-year-old man with a mass in the testisDonald S Kaufman
Department of Hematology-Oncology, Massachusetts General Hospital, USA
N Engl J Med 356:842-9. 2007 - Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancerJohn J Coen
Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
Urol Oncol 25:76-84. 2007..Radiation is a very effective palliative agent for patients with locally advanced or metastatic disease. It can palliate bleeding and pain for patients with local progression or alleviate pain from bony metastases... - Transitional cell carcinoma of the upper uroepithelial tractM Dror Michaelson
Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston, MA, USA
Clin Adv Hematol Oncol 1:102-4; discussion 105. 2003 - Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivorsAnthony L Zietman
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 302, Boston, MA 02114, USA
J Urol 170:1772-6. 2003..Concern exists about the function of the retained bladder after such therapy... - Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor
Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Urol 183:2200-5. 2010..We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer... - A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancerDonald S Kaufman
Massachusetts General Hospital, Boston, MA, USA
Urol Oncol 22:393-7. 2004..Insufficient patients with poor renal function or prior therapy were accrued to reach conclusions regarding its utility in these subgroups... - Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladderPaula D Ryan
Department of Medical Oncology, Massachusetts General Hospital, Boston, USA
N Engl J Med 354:850-6. 2006 - Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicityWilliam K Oh
Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Am J Clin Oncol 26:312-6. 2003..Neoadjuvant liposomal doxorubicin demonstrates no apparent activity and significant toxicity. New strategies are needed to improve outcomes in high-risk prostate cancer...